Loading…
One of China's largest independent clinical laboratories, running outsourced diagnostic testing for hospitals.
One of China's largest independent clinical laboratories, running outsourced diagnostic testing for hospitals.
Paid per test by hospitals that send samples out for analysis. A large COVID-testing business faded after China ended mass testing in late 2022, so routine and specialty testing now carries the company. Public-insurance pricing for tests influences what hospitals pay.
In one line: A Chinese LabCorp/Quest Diagnostics.
Moat: narrow (scale, installed base, regulatory licence). National lab network and hospital relationships are costly for smaller labs to replicate.
Headquarters: Guangzhou, Guangdong, China · Founded: 1994 · Employees: 9,529
Size Guangzhou Kingmed Diagnostics (603882.SS) is a China Health Care company (Medical/Nursing Services) with a market value of $1.99B, the 1272nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥28.63 on 6 Nov 2026.
Performance Over six months the shares gained 4.9%, against +25.1% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 3.5% over the last twelve months (peer median +5.9%); the operating margin is 7.3% (peer median 6.9%).
Valuation It trades at 31.7× forward earnings against a peer median of 40.3× (8th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.1 points above its cost of capital (7.8% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥5.89B | CN¥6.03B | CN¥7.19B | CN¥8.54B | CN¥15.5B |
| Revenue growth | — | -16% | -16% | -45% | — |
| Gross profit | CN¥2.37B | CN¥1.94B | CN¥2.22B | CN¥2.94B | CN¥6.52B |
| EBITDA | n/a | CN¥345M | CN¥471M | CN¥1.09B | CN¥3.88B |
| Net income | CN¥280M | -CN¥173M | -CN¥381M | CN¥643M | CN¥2.75B |
| Free cash flow | CN¥664M | CN¥790M | CN¥461M | CN¥516M | CN¥1.11B |
| Capital expenditure | CN¥465M | CN¥423M | CN¥446M | CN¥715M | CN¥841M |
| Total debt | CN¥853M | CN¥836M | CN¥748M | CN¥579M | CN¥568M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Guangzhou Kingmed Diagnostics 603882.SS | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% |
| Dian Diagnostics 300244.SZ | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% |
| ADICON 9860.HK | $408M | +9% | +1% | 4% | 25.5× | 12.0% |
| Labcorp LH | $29.8B | +45% | +6% | 11% | 19.0× | 13.9% |
| Quest Diagnostics DGX | $28.1B | +36% | +9% | 15% | 22.0× | 6.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603882.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.2% | +8.4% | 6th lowest of 21 |
| 6-month return | +4.9% | +25.1% | 6th lowest of 21 |
| Distance from 52-week high | -29.6% | -15.2% | 6th lowest of 21 |
| Revenue growth (TTM) | -3.5% | +5.9% | 4th lowest of 21 |
| Operating margin | 7.3% | 6.9% | 11th highest of 21 |
| Forward P/E | 31.7× | 40.3× | 8th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 6.7% | 13.4% | 7th least demanding of 16 |
| Growth delivered (Del g) | -6.1% | +8.9% | lowest of 16 |
| Hurdle (Req g minus delivered) | +12.7 pp | +3.5 pp | 6th most demanding of 16 |
| ROIC minus cost of capital | +3.1 pp | -3.3 pp | 3rd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% | -6.1% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% | -1.1% |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | n/a | 21.3% | +8.5% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 67.5× | n/a | n/a |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 98.7× | n/a | n/a |
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 58.9× | n/a | n/a |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 40.5× | 21.6% | +14.6% |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Addus HomeCare ADUS | United States | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% | +13.2% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 12.9× | -4.5% | +2.0% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| Aveanna Healthcare AVAH | United States | $2.89B | +97% | +20% | 11% | 15.4× | 13.4% | +10.2% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.89B | -9% | -4% | 9% | 55.1× | 5.8% | +5.7% |